Research on Alzheimer's disease, from early signs to new therapies. Covers screening tools, brain damage mechanisms, risk factors, sleep, and drug targets.
Researchers at Washington University School of Medicine studied 350 people to understand how Alzheimer's disease affects the brain. The study found that gene APOE is active in the areas most damaged by the disease, leading to symptoms like language and vision problems.
The FDA approved Aduhelm for Alzheimer's treatment based on reduced amyloid levels in the brain, despite no significant clinical effect. The use of amyloid-PET scans is being questioned for its accuracy and reliability in measuring amyloid removal.
The APOE4 gene variant increases the risk of Alzheimer's disease by disrupting the insulation of brain wiring. Research found that oligodendrocytes mismanage cholesterol, failing to transport fat molecules to myelinate axons. This deficiency may contribute to the pathology and symptoms of Alzheimer's.
Researchers have found that gossypetin from hibiscus activates microglia in the brain, which scavenge amyloid-beta aggregates to prevent cognitive decline. The study suggests a potential treatment for Alzheimer's disease using this flavonoid compound.
Scientists at King's College London and the University of Bath have made a groundbreaking discovery about a molecule that plays a crucial role in nerve cell development. The study found that this molecule, known as SNRNP70, is not only present in the nucleus but also in the cytoplasm of nerve cells, where it shapes messenger RNA strand...
A recent study by Brigham and Women's Hospital reveals that patients with Alzheimer's dementia and related disorders who also experience delirium incur significantly higher healthcare costs. The average additional cost for one delirium ADRD patient's year of care is $34,828 more than non-delirium ADRD counterparts.
A new study found racial and ethnic disparities in brain aging among middle-age and older adults. In late life, Latinx and white adults experienced more pronounced brain aging, while Black adults showed accelerated brain aging in midlife.
Researchers at Lund University have discovered that people with Alzheimer's disease can be identified before symptoms appear, using PET scans to visualize tau and amyloid proteins in the brain. Participants found to have these biomarkers were at a 20-40 times higher risk of developing cognitive decline in the next few years.
Researchers have identified a new biomarker, p-tau198, that could help diagnose Alzheimer's disease earlier than current tests. This biomarker shows promise in distinguishing AD from other neurodegenerative diseases and mild cognitive impairment.
Scientists at WashU Medicine have discovered that immune cells surrounding the brain play a crucial role in clearing toxic clusters of proteins. Treating old mice with an immune-stimulating compound rejuvenates these cells, improving waste clearance and holding promise for treating neurodegenerative diseases like Alzheimer's.
Researchers at Technical University of Munich developed synthetic peptides that bind to proteins forming amyloids, preventing their aggregation. These peptides could be valuable candidates for treating both diseases, with potential for medical application.
A study published in the Journal of the American Geriatrics Society found that antiepileptic prescribing to US nursing home residents with Alzheimer's Disease and dementia increased between 2015 and 2019. In contrast, antipsychotic and opioid prescribing rates declined during this period
Researchers have identified a new gene, NUCL-1, in the transparent roundworm C. elegans, which is linked to human neurodegenerative diseases such as ALS and Alzheimer's. The discovery challenges recent theories on the role of nuclear structures in these disorders.
Researchers found that extracts from hop flowers can inhibit the clumping of amyloid beta proteins, associated with Alzheimer's disease. The Tettnang hop extract showed potent anti-aggregation and antioxidant properties, promoting the body's ability to clear out misfolded proteins.
A new study published in Alzheimer's & Dementia found that telmisartan, a blood pressure medication, is associated with lower risk of Alzheimer's specifically in Black patients over 60. The study analyzed data from over 5 million patients and suggests that future clinical trials should prioritize minority populations to find or reinfor...
A study published in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring found that analyzing patients' speech can distinguish between different types of dementia. The research team developed a machine learning model using speech features to identify Alzheimer's disease and Lewy body dementia.
A study published in the Journal of Alzheimer's Disease found that analyzing patients' drawing tests can help diagnose Alzheimer's disease (AD) and distinguish it from dementia with Lewy bodies (DLB). The researchers discovered that DLB patients showed differences in speed-, pressure-, and pause-related features, whereas AD patients sh...
A new poll finds that more than half of people over 50 have helped at least one person over 65 with various tasks, including health care needs, home repairs, and finances. The experience can be rewarding but also challenging, especially for those helping individuals with complex needs.
Amanda Woerman's research aims to disrupt tau misfolding, a common thread in fatal neurodegenerative disorders PSP and CBD. The grant-funded study seeks to test a proof-of-concept gene therapy for these conditions, potentially leading to personalized medicine breakthroughs.
The study found that both aducanumab and donanemab had a large effect on removing beta-amyloid plaques, but with modest effects on slowing cognitive decline. The researchers developed a personalized treatment plan for individual virtual patients, minimizing side effects while optimizing dosage.
Donna Wilcock and her team are exploring the adverse effects of aducanumab and lecanemab on patients with Alzheimer's disease. They aim to understand how these immunotherapies cause Amyloid Related Imaging Abnormalities (ARIA) and find ways to prevent it.
A new study found that only 12% of middle-aged adults are willing to participate in dementia prevention drug trials, citing concerns over the risks involved. The study suggests prioritizing those with a family history or perceived personal risk for dementia and communicating about trial safety could increase participation.
The study provides detailed pictures of NMDA receptors, which mediate essential signals between neurons. The findings have significant implications for treating schizophrenia, depression, and other neuropsychiatric conditions.
A new funding grant will be used to investigate the effectiveness of 'Fastball EEG' in detecting three major types of dementia, including frontotemporal dementia and Vascular Dementia. The technology has shown high accuracy in picking up small changes in brain waves associated with memory recall.
A new computational model based on fruit fly brain data may help explain how humans process memories and experiences. The model suggests that living organisms, including humans, use a similar '1-2-3-many' count sketch to track encounters with familiar sights and smells.
A new study published in NEJM Evidence found that crossword puzzle training significantly improved cognitive function and daily activities, reducing brain shrinkage in individuals with mild cognitive impairment. The findings suggest that engaging with familiar activities like crossword puzzles may be more effective than computerized co...
A team of researchers at USC is launching a comprehensive study to investigate the connection between type 2 diabetes and dementia in adults with Hispanic ancestry. The five-year study will examine brain structure and activity, blood flow, blood glucose and insulin levels, and cognitive functioning in 200 participants.
Researchers will investigate immune system differences between men and women to better understand neurodegenerative diseases. The study aims to identify why certain neurological diseases primarily affect males or females, and how this difference impacts disease progression.
Researchers at Penn State aim to create a minimally invasive system using machine learning and multimodal biosensing platforms to detect Alzheimer's disease in its early stages. The system has the potential to improve detection accuracy and reduce false positives.
A study by CU Anschutz scientists found that overexpressing a gene tied to cell division boosts memory and learning in AD mice. Higher KIF11 levels also correlate with better cognitive performance in adults with amyloid pathology.
A new study by Université Laval researchers has identified a link between insulin receptors in brain microvessels and Alzheimer's disease. The findings suggest that drugs targeting these receptors could be effective in treating the condition, expanding the range of potential treatments.
A novel oxytocin derivative, PAS-CPPs-oxytocin, has been shown to improve cognitive function in mice with Alzheimer's-like symptoms. The derivative is delivered via intranasal administration and shows increased brain penetration compared to traditional intracerebroventricular delivery.
Researchers identified a compound that reverses damage to brain cells caused by Parkinson's disease and breaks a self-sustaining molecular loop between LRRK2 and AICD. The potential drug itanapraced has passed safety tests and could improve quality of life for those afflicted with PD and Alzheimer's disease.
A new study has discovered that MTCH2, a protein essential in various cellular processes, acts as a 'door' for proteins to access the mitochondrial membrane. The finding opens up potential avenues for cancer treatments by harnessing apoptosis, a programmed cell death mechanism.
Scientists uncover mechanism controlling cellular levels of tau, a protein linked to devastating neurodegenerative diseases. Overexpression of specific form of numb protein Numb-72 decreases tau levels and slows neuron loss in animal models.
A new radiotracer, 18F-SMBT-1, detects overexpressed monoamine oxidase-B in cognitively unimpaired individuals with high beta amyloid levels, a key early sign of Alzheimer's disease. The agent shows increased binding to reactive astrocytes, suggesting its potential as a surrogate marker for detecting Alzheimer's disease.
Researchers identified a kinase molecule that directs microglia activity, potentially treating neurodegenerative diseases like Alzheimer's and MS. The molecule, called spleen tyrosine kinase, targets plaque buildup and debris accumulation in the brain.
Researchers at Brigham and Women's Hospital identified ganglioside GM2 activator (GM2A) as a protein that may contribute to Alzheimer's disease progression. The protein reduces neuronal firing and induces loss of neurite integrity, suggesting its potential role in AD pathogenesis.
Researchers created a mouse model that demonstrates how RNA splicing defects contribute to neurodegeneration in Alzheimer's disease. The findings show that dysfunctional U1 snRNP leads to excitatory toxicity and accelerates cognitive decline, opening new avenues for treatment.
A nurse scientist at Kennesaw State University will conduct surveys and focus groups to develop effective caregiving strategies for Filipino-American caregivers. The research aims to promote health equity among these communities, which have scarce representation in healthcare research.
A recent UK Biobank study found that Black participants are at a higher risk of developing dementia compared to White participants, with an HR of 1.43. South Asians also have a similar risk to White participants. The study included 294,000 volunteers, but the results may not be representative of the wider UK population.
Researchers have identified cognitive impairment in patients with dementia-related diseases up to 9 years before diagnosis, raising hope for earlier interventions and clinical trial recruitment. The study analyzed UK Biobank data and found subtle impairments in problem-solving and memory across various conditions.
A recent study analyzed the records of over 33,000 dementia patients in Wales and found that those closest to their diagnosis were taking an average of three or more medications. This suggests a possible link between polypharmacy and the development of dementia.
Researchers found that higher levels of cell-free DNA in the blood are associated with increased cognitive decline and worsening frailty over an eight-year period. The study suggests that a simple blood test could detect risk of Alzheimer's disease and other forms of cognitive decline, potentially leading to early interventions.
The Keck School of Medicine's Stevens INI has received a nearly $2 million grant to upgrade its storage system, increasing its capacity to handle vast amounts of brain imaging data. This will enable the lab to maximize scientific productivity and fulfill its promise to collaborate with researchers globally.
Researchers analyzing over 3,000 blood samples from Alzheimer's patients and healthy individuals to identify reliable biomarkers. They investigate how well blood tests can diagnose Alzheimer's disease and predict its progression.
Researchers found positive correlations between lipoxin A4 and cognitive brain functions, as well as its potential to potentiate the endocannabinoid system. The study suggests that reducing levels of this substance may weaken the body's defenses against neurodegeneration.
A systematic review and meta-analysis found that psychotic disorders like schizophrenia are associated with a higher risk of developing dementia. People with psychotic disorders are 2.5 times more likely to develop dementia than those without a psychotic disorder, according to the review.
Researchers at Hokkaido University have developed a biosensing technology to detect amyloid β build-up in the brain from biomarkers in blood samples. The Digital ICA TM technology can detect Aβ-binding exosomes in mice, increasing with age and disease progression.
A study published in Nature has identified 61 additional genetic loci associated with stroke and six genes that are potential targets for drug therapy. The research also found a significant overlap between stroke and dementia, suggesting common biology between the two conditions.
A study published in Neurology found that eating omega-3 fatty acids can protect the brain from aging and cognitive decline in midlife. The research, conducted by the University of Texas Health Science Center at San Antonio, suggests that even small amounts of omega-3s can have a significant impact on brain health.
Researchers at Lancaster University found that 3D printed flavor-based cues can stimulate rich sensory accounts and strong emotional connections in older adults, recalling memories from their youth. This technology has potential applications for dementia care, allowing individuals to relive cherished moments through the power of smell.
A mouse study found that female brains express higher levels of an X-linked enzyme called USP11, leading to greater accumulation of tau protein and increased vulnerability to Alzheimer's disease. The results suggest that excessive activity of USP11 drives this increased susceptibility in females.
Researchers have designed a smart cell-based delivery system to treat Alzheimer's disease by targeting multiple pathologies, reducing the risk of side effects. The system uses bio-synthesizable drugs and immune cells to deliver combination therapy that addresses all pathologies in a targeted manner.
Women are more susceptible to Alzheimer's disease due to higher expression of the enzyme ubiquitin-specific peptidase 11 (USP11), which drives increased accumulation of tau protein in brain nerve cells. Researchers hope to develop new neuroprotective medicines based on this finding.
A new study found that fewer Asian, Black, and Hispanic patients qualify for anti-amyloid monoclonal antibody treatments, which may slow Alzheimer's progression. The treatment's effectiveness depends on the presence of amyloid plaques, with lower incidence in minorities.
The Keck School of Medicine of USC's Stevens INI has received a $149 million grant to study Alzheimer’s disease among diverse communities. The HABS-HD study aims to develop biomarkers that determine risk for developing the disease, addressing health disparities among Hispanic and African American populations.
A study of 226 Alzheimer's family caregivers found that 61.5% experienced depressive symptoms at diagnosis, with 1 in 3 showing worsening symptoms over five years. The risk was not linked to disease severity or individual backgrounds.
Researchers developed a machine learning model to quickly recognize predictive risk factors and their importance for undesirable hospitalization outcomes. The model achieved an accuracy of 95.6% and identified modifiable risk factors that can be mitigated through clinical interventions.
Alzheimer's researchers highlight the need for more diverse participation in clinical trials, citing underrepresentation of African Americans and Latinos. They offer solutions to improve recruitment, including culturally sensitive cognitive tests and partnerships with community organizations.